• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Affimed N.V. - Common Stock (NQ: AFMD )

    1.250 +0.010 (+0.81%)
    Streaming Delayed Price Updated: 12:39 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 155,882
    Open 1.220
    Bid (Size) 1.250 (6)
    Ask (Size) 1.270 (6)
    Prev. Close 1.240
    Today's Range 1.210 - 1.330
    52wk Range 1.144 - 8.950
    Shares Outstanding 15,227,463
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
    From Affimed N.V.
    Via GlobeNewswire

    Performance

    YTD
    -80.00%
    -80.00%
    1 Month
    -58.33%
    -58.33%
    3 Month
    -62.24%
    -62.24%
    6 Month
    -77.56%
    -77.56%
    1 Year
    -72.56%
    -72.56%

    More News

    Read More
    Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
    From Affimed N.V.
    Via GlobeNewswire
    A Look Ahead: Affimed's Earnings Forecast
    Via Benzinga
    Why Affimed Shares Are Soaring
    Via Benzinga
    Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Reports Third Quarter 2024 Financial Results & Business Update
    From Affimed N.V.
    Via GlobeNewswire
    Earnings Scheduled For November 14, 2024
    Via Benzinga
    Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
    From Affimed N.V.
    Via GlobeNewswire
    Affimed to Present at the Cantor Global Healthcare Conference 2024
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Reports Second Quarter 2024 Financial Results & Business Update
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Appoints Shawn M. Leland as Chief Executive Officer
    From Affimed N.V.
    Via GlobeNewswire
    Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
    From Affimed N.V.
    Via GlobeNewswire
    AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Affimed Reports First Quarter 2024 Financial Results & Business Update
    From Affimed N.V.
    Via GlobeNewswire
    Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
    From Affimed N.V.
    Via GlobeNewswire
    Why Is German Biotech Affimed Stock Soaring On Monday?
    Via Benzinga
    Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
    From Affimed N.V.
    Via GlobeNewswire
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
    From Affimed N.V.
    Via GlobeNewswire
    Affimed Announces Annual General Meeting of Shareholders
    From Affimed N.V.
    Via GlobeNewswire
    7 Penny Biotech Stocks to Triple Your Investment
    Via InvestorPlace
    Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
    From Affimed N.V.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.